Printer Friendly

Teva launches generic version of Letairis.

Teva Pharmaceutical Industries (TEVA) announced the launch of a generic version of Letairis Tablets, 5 mg and 10 mg, in the U.S. Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. For all female patients, ambrisentan tablets are only available through a restricted program called the Ambrisentan Risk Evaluation & Mitigation Strategy due to the risk of fetal harm. Letairis has annual sales of nearly $247 million in the U.S., according to IQVIA (IQV) data as of February 2019.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:May 1, 2019
Previous Article:Powell: analysts don't see a strong case for a rate move either way.
Next Article:Treasury Action: markets have whipsaw as Powell stressed the transitory nature.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters